First human trial launches for experimental blood cancer treatment
NCT ID NCT06372717
Summary
This early-stage study is testing a new drug called APL-4098 to see if it's safe and effective for adults with advanced forms of blood cancer that have returned or stopped responding to other treatments. Researchers will give APL-4098 alone and in combination with two standard cancer drugs to about 100 participants. The main goal is to find the safest dose and understand how the body processes the drug.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA REFRACTORY are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Hollywood Private Hospital
RECRUITINGNedlands, Western Australia, 6009, Australia
-
Monash Health
RECRUITINGClayton, Victoria, 3168, Australia
-
Royal Perth Hospital
RECRUITINGPerth, Western Australia, 6000, Australia
-
Sarah Cannon Research Institute UK
RECRUITINGLondon, W1G 0PU, United Kingdom
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
St. Vincent's Hospital Melbourne
RECRUITINGFitzroy, Victoria, 3065, Australia
-
The Alfred Hospital
RECRUITINGMelbourne, Victoria, 3004, Australia
-
The Royal Marsden Hospital
RECRUITINGLondon, SM2 5PT, United Kingdom
Conditions
Explore the condition pages connected to this study.